Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
173 stopped studies mapped to Malignant Biliary Tract Neoplasm and descendants · 92% state a reason
Over the 173 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04186156 | A Study of Selective HDAC6 Inhibition With KA2507 in Advanced Biliary Tract Cancer | Phase 2 | withdrawn | Dec 4, 2019 | Karus Therapeutics Limited | Study not progressing | Other (stated, no rule matched) |
| NCT02992340 | Varlitinib in Combination With Gemcitabine and Cisplatin for Treatment naïve Advanced or… | Phase 1 / Phase 2 | terminated | Dec 14, 2016 | ASLAN Pharmaceuticals | Sponsor decided to terminate the study and not proceed to Phase 2. | Sponsor / business decision |
| NCT02597465 | A Randomized, Open-Label, Comparative, Parallel-Group, Multicenter Study of SPARC1507 | Phase 3 | withdrawn | Nov 5, 2015 | Sun Pharma Advanced Research Company Limited | Sponsor decided not to initiate the study for alternate commercial strategy | Sponsor / business decision |
| NCT03563352 | Nutritional Preferences and Product Accessibility in Oral Nutritional Supplements in… | — | withdrawn | Jun 20, 2018 | University of Southern California | Zero accrual | Enrollment / accrual |
| NCT02757391 | CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic… | Phase 1 | terminated | May 2, 2016 | M.D. Anderson Cancer Center | Study halted prematurely and will not resume; participants are no longer being examined or… | Other (stated, no rule matched) |
| NCT02012231 | Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in… | Phase 1 | terminated | Dec 16, 2013 | Fore Biotherapeutics | not stated | Not stated |
| NCT03579758 | Chemotherapy Before & After Surgery in Patients With Resectable Gallbladder Cancer | Phase 3 | withdrawn | Jul 9, 2018 | Emory University | This trial will open as an NCTN trial. | Other (stated, no rule matched) |
| NCT03801499 | Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma | Phase 2 | withdrawn | Jan 11, 2019 | Sun Yat-sen University | Protocol modification | Other (stated, no rule matched) |
| NCT03768531 | Safety and Tolerability Study of Nivolumab and Cabiralizumab for Resectable Biliary Tract… | Phase 2 | withdrawn | Dec 7, 2018 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | No subjects were enrolled | Enrollment / accrual |
| NCT03172832 | A Trial of Percutaneous vs. Endoscopic Drainage of Suspected Klatskin Tumors(INTERCPT) | N/A | terminated | Jun 1, 2017 | Medical University of South Carolina | Slow accrual; recommended by DSMB. | Enrollment / accrual |
| NCT03267940 | Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab… | Phase 1 | terminated | Aug 31, 2017 | Halozyme Therapeutics | Sponsor decision | Sponsor / business decision |
| NCT03818997 | Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric…(DYNAMIC) | Phase 2 | withdrawn | Jan 28, 2019 | European Organisation for Research and Treatment of Cancer - EORTC | Company decision | Sponsor / business decision |
| NCT03211169 | Comparison Bile Duct Brushings, Cholangioscopy-Directed Biopsies and Pediatric Forceps… | N/A | terminated | Jul 7, 2017 | Stanford University | Inadequate enrollment | Enrollment / accrual |
| NCT02082522 | Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar… | Phase 3 | terminated | Mar 10, 2014 | Concordia Laboratories Inc. | Accrual rate remaining too low | Enrollment / accrual |
| NCT00478140 | Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer… | Phase 2 | terminated | May 24, 2007 | National Cancer Institute (NCI) | Due to slow accrual | Enrollment / accrual |
| NCT02955771 | Efficacy and Safety Study of PDT Using Deuteporfin for Unresectable Advanced Perihilar… | Phase 2 | terminated | Nov 4, 2016 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Business Decision | Sponsor / business decision |
| NCT03779100 | Lenvatinib Plus PD-1 Antibody for Unresectable ICC | Phase 2 | suspended | Dec 19, 2018 | Shi Ming | Protocol modification | Other (stated, no rule matched) |
| NCT01855724 | Clinical Trial to Investigate the Efficacy of Treatment With Gemcitabine/Pazopanib in… | Phase 2 | terminated | May 16, 2013 | Hellenic Cooperative Oncology Group | not stated | Not stated |
| NCT02254681 | Low-Dose Radiation Therapy to the Whole Liver With Gemcitabine and Cisplatin in IHC | Phase 2 | terminated | Oct 2, 2014 | Allina Health System | lack of funding | Funding |
| NCT02204124 | Whipple Procedure: Standard of Care vs. Thunderbeat | N/A | terminated | Jul 30, 2014 | Washington University School of Medicine | Principal Investigator and Study Sponsor decided to terminate the study early | Investigator |
| NCT00832637 | Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers(Gem-ox) | Phase 2 | terminated | Jan 30, 2009 | New Mexico Cancer Research Alliance | Low accrual | Enrollment / accrual |
| NCT02374489 | A Phase II Trial of LDK378 in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or… | Phase 2 | terminated | Feb 27, 2015 | National Health Research Institutes, Taiwan | ROS1 in IHC and gene rearrangement result can not match。No tumor response。 | Other (stated, no rule matched) |
| NCT02638909 | Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal… | Phase 2 | terminated | Dec 23, 2015 | Criterium, Inc. | Lack of Enrollment | Enrollment / accrual |
| NCT00588263 | Anonymous Testing of Pathology Specimens for BRCA Mutations in Ashkenazi Jewish… | — | withdrawn | Jan 8, 2008 | Memorial Sloan Kettering Cancer Center | Data from MSK-IMPACT is sufficient for relevant analyses going forward | Other (stated, no rule matched) |
| NCT02105350 | A Study of MEK162 With Gemcitabine and Oxaliplatin in Biliary Cancer | Phase 1 | withdrawn | Apr 7, 2014 | University Health Network, Toronto | Study was never initiated | Other (stated, no rule matched) |
| NCT03081039 | A Study of Cisplatin or Carboplatin With Gemcitabine Versus Gemcitabine Alone as Adjuvant… | Phase 3 | withdrawn | Mar 15, 2017 | University of Louisville | Competing study | Other (stated, no rule matched) |
| NCT01721174 | Endoscopic Biliary Radiofrequency Ablation of Malignant Distal Common Bile Duct Strictures | N/A | terminated | Nov 5, 2012 | Chinese University of Hong Kong | Poor recruitment | Enrollment / accrual |
| NCT02720601 | Irinotecan and Capecitabine as Second-line Treatment for Advanced/Metastatic Biliary… | Phase 2 | withdrawn | Mar 28, 2016 | New Mexico Cancer Research Alliance | Study was never submitted to the IRB \& never opened. PI is leaving institution. | Other (stated, no rule matched) |
| NCT00955721 | A Study of Combination of Gemcitabine, Oxaliplatin (GEMOX)-Sorafenib in Patients With… | Phase 1 / Phase 2 | terminated | Aug 10, 2009 | University of Miami | Lack of Funding | Funding |
| NCT00903396 | Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy… | Phase 2 | terminated | May 18, 2009 | Alliance for Clinical Trials in Oncology | Slow accrual | Enrollment / accrual |
| NCT02106871 | Study of Sildenafil as a Therapy for Fatigue in Pancreatic Cancer(PCC) | Phase 1 | withdrawn | Apr 8, 2014 | The University of Texas Medical Branch, Galveston | Study did not get funded. Study never started | Funding |
| NCT00386516 | Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile… | Phase 2 | withdrawn | Oct 11, 2006 | Galectin Therapeutics Inc. | Financing and re-organization | Funding |
| NCT00085410 | Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic… | Phase 2 | terminated | Jun 11, 2004 | National Cancer Institute (NCI) | The trial was discontinued early due to no confirmed partial responses. | Other (stated, no rule matched) |
| NCT02856568 | Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With… | Phase 1 | withdrawn | Aug 5, 2016 | Mayo Clinic | Site dropped study | Other (stated, no rule matched) |
| NCT01303159 | Endoscopic Bipolar Radiofrequency Probe (ENDOHPB) in the Management of Unresectable Bile… | N/A | terminated | Feb 24, 2011 | Weill Medical College of Cornell University | EndoHPB probe is FDA approved and considered standard of care | Other (stated, no rule matched) |
| NCT00604266 | Coregistration of 18F-FDG-PET and MRI in the Staging of Potentially Resectable Hilar…(PET/MRCP) | — | withdrawn | Jan 30, 2008 | University of Toronto | not stated | Not stated |
| NCT01543607 | Endoscopic Therapy of Malignant Bile Duct Strictures | N/A | terminated | Mar 5, 2012 | Massachusetts General Hospital | Lack of enrollment | Enrollment / accrual |
| NCT03117855 | Capecitabine and Y-90 Radioembolization in Treating Patients With Advanced Bile Duct… | Phase 1 | withdrawn | Apr 18, 2017 | City of Hope Medical Center | Company no longer interested in supporting this trial | Sponsor / business decision |
| NCT01229111 | Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary… | Phase 2 | terminated | Oct 27, 2010 | National Cancer Institute (NCI) | Lack of Drug Supply | Drug supply |
| NCT02446379 | Use of the EnLightTM and LightPathTM Imaging Systems in Gastrointestinal Tumour Surgery(CLIO) | — | withdrawn | May 18, 2015 | Lightpoint Medical Limited | Technology licensed to third party. Sponsor did not proceed with study. | Other (stated, no rule matched) |
| NCT01151761 | Phase II SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver… | Phase 2 | terminated | Jun 28, 2010 | Stanford University | Poor accrual | Enrollment / accrual |
| NCT00767234 | Permission to Collect Blood Over Time for Research | — | terminated | Oct 7, 2008 | Stanford University | Accrual issues - Low Accrual | Enrollment / accrual |
| NCT01875549 | Comparison Between Unilateral Versus Bilateral Stenting for Malignant Hilar Biliary… | N/A | withdrawn | Jun 12, 2013 | Kwang Hyuck Lee | no enrollment | Enrollment / accrual |
| NCT00975039 | Study Using WST11 in Patients With Non-Resectable or Inoperable Cholangiocarcinoma | Phase 2 | terminated | Sep 11, 2009 | Steba Biotech S.A. | Early end of enrolment with regards to difficulty met to enrol patients . | Enrollment / accrual |
| NCT02479178 | A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical…(iNSITE2) | Phase 2 | terminated | Jun 24, 2015 | BIND Therapeutics | not stated | Not stated |
| NCT00414843 | Storage of Bile From Routine Procedures to Study Risk Factors | — | terminated | Dec 22, 2006 | Indiana University | Decreasing interest in using samples; department infrastructure waned | Other (stated, no rule matched) |
| NCT01501604 | BKM120 in Cancers With PIK3CA Activating Mutations | Phase 2 | withdrawn | Dec 29, 2011 | Massachusetts General Hospital | The study has been closed due to lack of accrual | Enrollment / accrual |
| NCT00630890 | Cyberknife Radiosurgery Boost for Hilar Cholangiocarcinoma (Klatskin Tumor) | Phase 1 | terminated | Mar 7, 2008 | University of California, San Francisco | investigator left UCSF and study was closed prematurely in 2008. No results to report. | Investigator |
| NCT00624182 | Gemcitabine With Peptide Vaccine Therapy in Treating Patients With Bile Duct Cancer | Phase 1 | suspended | Feb 26, 2008 | Akita University Hospital | not stated | Not stated |
| NCT01775280 | Response of Hepatic Tumors to Radioembolization(RESRAD) | Phase 2 | withdrawn | Jan 24, 2013 | University of Zurich | Lack of enrollment | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Feb 3, 2021source: clinicaltrials